6497 Aslan Pharmaceuticals

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference. The conference will be held virtually from April 11 to 14, 2022.

Presentation details

Date: Thursday, April 14, 2022

Time: 10:15 - 10:55am ET

Format: Company presentation

Track: 2

Click to listen-in live or via replay. This link will also be posted in the News & Events section of ASLAN Pharmaceutical’s Investor Relations website at .

Ends



Media and IR contacts

Emma Thompson

Spurwing Communications

Tel:

Email:

Ashley R. Robinson

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email:

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit  or follow ASLAN on .



EN
06/04/2022

Underlying

6497Aslan Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aslan Pharmaceuticals

 PRESS RELEASE
Free
6497 Aslan Pharmaceu...

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthc...

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022 MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference. The conference will be held virtually from April 11 to 14, 2022. Presentation details Date: Thursday, April 14, 2022Time: 10:15 - 10:55am ETFormat: Compa...

April 6, 2022 1 EN
 PRESS RELEASE
Free
6497 Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Re...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement MENLO PARK, Calif. and SINGAPORE, April 01, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on March 28, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of ...

April 1, 2022 1 EN
 PRESS RELEASE
Free
6497 Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From...

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting MENLO PARK, Calif. and SINGAPORE, March 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab (ASLAN004) in moderate-to-sever...

March 28, 2022 1 EN
 PRESS RELEASE
Free
6497 Aslan Pharmaceu...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financ...

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023New CMO appointed, adding senior global pharma experience to the leadership team Company maintains strong operating position with US$90.2 million in cash and cash equivalents as of December 31, 2021, runway through late 2023Replays available for company-hosted A4 KOL series on AD landscape; next event to be held in the second quarter ME...

March 25, 2022 1 EN
 PRESS RELEASE
Free
6497 Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract o...

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting - Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking Research: Clinical Trials” session at the 2022 American Academy of Dermatology Annual Meeting on March 26 MENLO PARK, Calif. and SINGAPORE, March 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutica...

March 18, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch